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Background: Nijmegen Breakage Syndrome (NBS) is a rare autosomal recessive DNA repair disorder characterized
by immune deficiency, microcephaly, mental retardation and a disposition for the development of hematological
malignancies. So far, mostly pediatric patients have been described, since the underlying condition is often fatal
before adulthood. Many patients diagnosed with Hodgkin lymphoma (HL) due to this DNA repair defect receive
reduced treatment followed by early progression and fatal outcome.
Case presentation: We describe here a 26-year old male caucasian patient with NBS who presented with multi
organ failure due to HL. Immediate intensive chemotherapy lead to complete remission and reversed organ failure.
Conclusion: We show that application of standard chemotherapy can lead to long-term disease free survival in
patients with a DNA repair disorder. Furthermore, we describe here, to the best of our knowledge, the first adult
patient with NBS and HL.
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Nijmegen Breakage Syndrome (NBS) is a rare autosomal
recessive DNA repair disorder [1] characterized by a 5 bp
deletion in the NBS1 gene on chromosome 8q21, which
leads to a truncated and insufficiently functioning protein
Nibrin [2]. By mediating the phospho ATM-driven assem-
bly of BRCA, MRE11 and Rad50 on double strand breaks,
nibrin carries a central role in the cellular response to
DNA damage [3]. Homozygous state of the above men-
tioned mutation causes immune deficiency, microcephaly,
mental retardation and a disposition for the development
of leukemias as well as Hodgkin and Non-Hodgkin
lymphomas (HL; NHL) [4-6]. To the best of our know-




A 23 year old male was referred to our intensive care
unit from an outside hospital with hepatic and renal fail-
ure (serum bilirubin 41 mg/dl, International Normalized* Correspondence: katharina.engel@lrz.tu-muenchen.de
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reproduction in any medium, provided the orRatio (INR) 1.7, Blood Urea Nitrogen (BUN) 108 mg/dl,
serum creatinin 5.3 mg/dl).
Three weeks earlier the patient had presented to an out-
side hospital with increasing fatigue and cervical swelling
over several weeks. Biopsy of the cervical lymph nodes had
established the diagnosis of nodular sclerosing classical
HL. Staging was done by whole body MRI scan (Figure 1)
and revealed a large cervical lymph node bulk (8 × 3.3 cm)
on the left side and slightly enlarged cervical, paratracheal
and paraaortal lymph nodes on the right side. Moreover,
there were two small masses in the left lung (13 mm and
7 mm in diameter, respectively) as well as multiple hepatic
nodules. Further laboratoy work-up was notable for in-
creased Erythrocyte Sedimentation Rate (ESR) of 96 mm/
h, and immunodeficiency (lymphocytopenia, T helper cell
and B cell count significantly decreased, IgG4 deficiency).
Histological examination of the bone marrow showed no
infiltration by HL.
The patient was also known to suffer from NBS. He was
diagnosed at birth and registered in the NBS Registry as
patient No. 45. In accordance with this diagnosis he dis-
played mild mental retardation (he had been working as
an auxiliary cook up to this point), microcephaly, charac-
teristic facial features as well as an immune defect. He was
known to suffer from selective IgG4 deficiency and histd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Initial radiologic staging confirming lymphoma Ann Arbor stage IV. (A) T1 weighted images after i.v. contrast administration
demonstrate left cervical lymphadenopathy (arrows). (B) Pathological enlargement and contrast uptake is also noted in left supraclavicular
(arrows) and right paratracheal (dotted arrow) lymph nodes. Delayed phase VIBE sequence demonstrates a lung nodule (C) and left paraaortic
lymphadenopathy (D). Multiple hypointense liver lesions are noted in the VIBE sequence acquired in portal venous phase (E + F). These findings
are consistent with HL with nodal, hepatic and pulmonary involvement.
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sensitive to induction of DNA breaks (The International
Nijmegen Breakage Study Group [7]). Up until this young
adult age he had no history of severe infections.
During the initial evaluation the patient was withdrawn
from further medical care by his parents. When he devel-
oped B symptoms and his condition rapidly deteriorated
he was readmitted and transferred to our hospital. The pa-
tient measured 1,52 m with a weight of around 75 kg; he
presented awake and oriented, but severely icteric, anuric
and edematous. On admission, a little over two weeks
after the diagnosis had been established, he was in acuterenal and hepatic failure. Treatment with Prednisone
100 mg i.v. daily had been started.
Clinical course
Ultrasound-guided biopsy of liver nodules was per-
formed immediately and showed multiple small nodular
infiltrates of classical Hodgkins lymphoma (Figure 2).
Therefore, diagnostic stage had to be corrected to IVB
and systemic chemotherapy similar to CHOP schedule
was started, however adapted to poor renal and hepatic
function. He received reduced CHOP-like chemother-
apy including cyclophosphamide 375 mg/qm (50%),
Figure 2 Liver Biopsy documenting hepatic involvement of Hodgkin’s lymphoma. (A) Histology of classical HL with lacunar cells and mixed
inflammatory background. Hodgkin cells express a characteristic immunophenotype with strong positivity for CD30 (B) and weak expression of
CD20 (C). CD15 staining (A) highlights few histocytes. (D) Histology of classical HL with lacunar cells and mixed inflammatory background.
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on day 3 of the hospital stay.
Citrate hemodialysis was initiated immediately and
continued for the following four weeks. During this time
renal function started to improve. Additionally, after ap-
plication of the first cycle of chemotherapy, albumin dia-
lysis was applied several times until hepatic function
started to recover.
While organ functions were improving following appli-
cation of chemotherapy, the patient developed aspergillus
fumigatus and candida albicans pneumonia, confirmed by
culture of bronchioalveolar fluid, and had to be ventilated
for ten days. White blood counts were stimulated using
granulocyte colony stimulating factor (G-CSF) starting on
day 4 after chemotherapy application. Twenty-one days
after the first chemotherapy, the patient received the sec-
ond cycle, this time an attenuated ABVD schedule (adria-
mycin d1 75% and d15 100%, bleomycin d1 25% and d15
50%, vinblastin d1 75% and d15 100%, dacarbazin d1 50%
and d15 75%). During the second cycle he again became
septic from Candida urinary tract infection but recovered
in due time with caspofungin treatment and G-CSF sup-
port to receive the next dose of chemotherapy on day 15.
Overall, we applied four cycles of chemotherapy, three of
them ABVD d1 and d15, and were able to escalate the
doses of adriamycin, bleomycin and vinblastin to 100%,
and of dacarbazin to 75% of the regular adult schedule. Indetail, the following doses (given as total or per m2 body
surface area) were applied. Cycle 1: cyclophosphamide
375 mg/m2, doxorubicin 12,5 mg/m2, vincristin 2 mg total
dose; cyclophosphamide was reduced to limit hematotoxi-
city considering renal failure; doxorubicin dose was ad-
justed to poor liver function. Cycle 2 (3 weeks later), d1:
doxorubicin 19 mg, bleomycin 2,5 mg, vinblastin 4,4 mg,
dacarbazin 194 mg, all per m2. doxorubicin was still ap-
plied in a lower dose to account for hepatic dysfunction,
bleomycin was thought to be particularly toxic since it in-
duces DNA breaks, especially in kidney failure. Since the
patient was still recovering from severe sepsis also vin-
blastin and dacarbazin were reduced to limit the risk of
neutropenic infection. Pegylated G-CSF was given d4 and
d19. Cycle 2, d15: doxorubicin 25 mg, bleomycin 5 mg,
vinblastin 6 mg, dacarbazin 281 mg, all per m2. Cycle 3
and cycle 4, d1 and d15: doxorubicin 25 mg, bleomycin
10 mg, vinblastin 6 mg, dacarbazin 281 mg, all per m2.
However, the patient was affected with severe intensive
care polyneuropathy leading to lower extremities paresthe-
sias and paralysis. The situation was further complicated
by grade IV anal ulcer and eventually a depressive episode.
The resulting refusal to co-operate prevented mobilisation
as well as implementation of supportive measures and sta-
ging procedures. Therefore, and in consideration of the
dramatic clinical response already obtained it was decided
together with his family to terminate chemotherapy. After
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intensive psychotherapy the patient was referred to a re-
habilitation facility for the following eight weeks and then
discharged home.
Follow-up MRI was performed at 3, 6, 12 and 18
months after initial diagnosis and continued to show
complete remission. At 20 months after the initial diag-
nosis, the patient has now regained full mobility, does
not exhibit any clinical sequelae of the disease and has
started to work again as an auxiliary cook. His mental
condition has returned to baseline without pharmaco-
logic intervention.
Conclusions
NBS is an autosomal recessive DNA repair disorder
similar to Ataxia Teleangiectasia (AT), which predis-
poses for the development of HL and NHL. So far, 25
pediatric, adolescent and young adult patients with DNA
repair disorder – Ataxia Teleangiactasia or Nijmegen
Breakage Syndrome - and HL have been identified [8,9].
The median age at time of diagnosis was 9.4 years with
two ATM patients being of adult age (20 and 25 years).
One NBS patient with HL described in the literature was
six years old and died 12 months after diagnosis [8]. The
other, a five-year old, however, reached sustained remis-
sion after intensive chemotherapy [10]. To the best of our
knowledge we here describe the first adult patient with
NBS and HL.
Although the pathogenetic basis of both conditions re-
semble each other, NBS and AT display distinct clinical
features. NBS, first described in 1981 [11], is character-
ized by microcephaly, typical facies, immunodeficiency,
and chromosomal instability [1]. It lacks the typical cere-
bellar ataxia that lends its name to AT, but shares the
tendency to develop lymphoid malignancies [6,12].
Our patient was affected with microcephaly, reduced
intelligence and the typical craniofacial features but never
suffered from severe infectious complications despite the
lymphocytopenia, IgG4 deficiency and chromosomal in-
stability. When sequencing of the NBS1 gene was per-
formed at the time of diagnosis no known mutations were
identified. Parental genotyping was declined. The patient
was thus included into the Nijmegen Breakage Registry
based on clinical signs and symptoms, i.e. microcephaly,
immunodeficiency and chromosomal instability. Among
the cases published within the first report of the Nijmegen
Breakage Registry in 2000 [7], in nine out of 55 (16%) pa-
tients no mutation was identified and 37 children (67%)
presented without a family history.
The overall mild phenotype might explain the late onset
of malignant disease: with an age of 23 years he is the
second oldest patient with HL and DNA repair disorder
described so far. The most common NBS1 mutation
(c.675del5) is hypomorphic [13] and indirectly leads toa N terminally truncated, alternatively translated NBS
protein (p70), the level of which determines damage
sensitivity in lymphoid cells. Likewise, our patient’s gen-
etic aberration might give rise to a particularly high
level of functioning truncated Nibrin protein. However,
the genotype-phenotype correlation is unsatisfactory [7]
and our patient’s mild phenotype in childhood and ado-
lescence was probably more predictive for treatment toler-
ance and success than the genetic background could have
been.
Although the majority of patients with DNA repair dis-
order and HL are diagnosed in a far advanced stage of the
malignancy [14] the presence of multi organ failure in this
clinical setting has not been reported so far. While liver
failure was clearly due to HL infiltration, the origin of
renal failure could have been a consequence of either sep-
sis or high cell turn-over but was certainly aggravated by
hypovolemia (high fever without adequat fluid substitu-
tion) and hepato-renal mechanisms. Tumor infiltration of
the kidneys appears unlikely as this was not identified on
magnetic resonance scan. Patients with stage IV disease at
diagnosis (HL or NHL or other malignancies accompany-
ing this disorder) never survived more than half a year
[14]. In our case, the early and rather aggressive initial
treatment (anthracyclin, vinca alkaloid and alkylating
agent) completely restored organ function by leading to
fast and sustained remission of HL. However, the patient
described here suffered from two episodes of severe infec-
tion, both from fungi rather than bacteria. It has been de-
scribed that the incidence of fungal infections is higher in
NBS patients due to reduced cellular and humoral im-
munity [15]. In our patient, who had never suffered from
infectious complications before, chemotherapy-induced
neutropenia might have tipped him over the edge to sys-
temic fungal infection.
Although the patient might have to face secondary ma-
lignancy from treatment within the next years, the hith-
erto clinical course provides strong support for an initial
standard ABVD treatment strategy in patients with un-
derlying DNA repair disorder. Importantly, additional iat-
rogenic DNA damage should be avoided using clinical
examination as well as MRT or PET-MRT instead of CT
for imaging.
In summary, this is – to the best of our knowledge -
the first adult patient with NBS and HL described so far.
Despite presenting with multiple organ failure and stage
IV disease, he achieved sustained remission with early
standard chemotherapy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. At the time of publication the patient himself
was able to evaluate his consent despite his mild mental
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he was legally represented by his parents. Therefore,
consent for publication of this work was also obtained
from them. A copy of the written consent is available for
review by the Editor of this journal.
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